Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q1 FY2022-23 Earnings Presentation
17 slides from Thyrocare Technologies's earnings presentation, Aug 1, 2022
Slide 1: Exchange filing cover letter for Q1 results presentation
Auggust 01, 20222 The National Stoock Exchangge of India Liimited The Bom mbay Stock Exchange E Lttd Exchhange Plaza Phiroze Jeejeeboy Towers T Banndra Kurla Coomplex, Dalal Sttreet, mbai - 400 051 Banndra (E), Mum Mumbai- 400 001 (SYM MBOL: THYR ROCARE) (SCRIP CODE C 539871) Deaar Sirs/Madam m, Sub
Slide 2: Thyrocare Technologies Limited – Quarter Results Q1 FY22-23
Thyrocare Technologies Limited Quarter Results – Q1 FY22-23 0
Slide 3: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 1
Slide 4: A new brand identity and brand logo
A new brand identity and brand logo which reflects our dynamism as a bigger and widely trusted brand Element – Drop of Blood Blood is a symbol of life and it signifies our heritage in pathology testing which is at the core of the company From a journey that began in 1996 with only three tests – T3,
Slide 5: Continued efforts on focus areas to drive sustainable growth
Continued efforts on focus areas which we highlighted to drive sustainable growth Geography • Pin Expansion: 1000 new pins activated in AMJ (1+ sample billed) Expansion • Lab Expansion: 2 New RPLs started at Vishakhapatnam and Jaipur Customer • Franchisee connect: Invested in franchisee support, a f
Slide 6: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 4
Slide 7: Quarter Health-check
Quarter Health-check YoY Non-Covid Revenue YoY Non-Covid EBITDA QoQ Non-Covid Revenue +33% +27% +12% YoY Non-Covid samples YoY Non-Covid Tests YoY Radiology Revenue +57% +44% (6 Mn samples (35 Mn tests +59% in this Q) in this Q) YoY Covid Revenue YoY Total Revenue* YoY Non-Covid EBITDA % -96% -22% -
Slide 8: We have consistently delivered 10%+ QoQ growth for 2 quarters
We have consistently delivered 10%+ QoQ growth for 2 quarters Significant growth in Non COVID over last year Focus on recovery of Non COVID business Pathology Revenue (Rs Cr) Pathology Revenue (Rs Cr) QoQ Non COVID Growth 159.3 +10% +10% +12% +12% 119.2 123.3 119.2 68.4 2.7 110.7 16.1 2.7 15.3 112.2
Slide 9: We continue to sustain our March performance, both in revenue and workload
We continue to sustain our March performance, both in revenue and workload Diagnostic Services Revenue (excludes Material Sales) (Rs Cr) Diagnostic Services Workload (Lakhs) Non COVID 50 30 COVID 41 40 38 37 38 All time high 34 33 34 21 31 31 32 32 30 29 28 28 20 18 19 19 30 28 +12% 24 24 14 14 15 +
Slide 10: B2B and B2C verticals have stabilized; B2B volume growth of 19%
Our B2B and B2C verticals have stabilized ; B2B vertical continues to post a strong Q-O-Q volume growth of 19% Non COVID Diagnostics Services Revenue (Rs Cr) Non COVID Diagnostics Services Workload (Lakhs) 18 30 28 28 28 16 16 16 25 24 24 23 23 23 23 23 21 21 +14% 12 12 +19% 12 11 11 11 19 +10% B2B
Slide 11: Non COVID P&L has improved QoQ, but COVID P&L continues to decline
Non COVID P&L has improved QoQ, but COVID P&L continues to decline Non COVID COVID Q1’22 Q4’22 Q1’23 Q1’22 Q4’22 Q1’23 Revenue 90.83 107.20 116.52 68.43 16.13 2.69 Drop in revenues on account of drop in COVID cases, people opting for at-home testing through kits and relaxation in travel regulations
Slide 12: Income Statement – Pathology
Income Statement – Pathology: Marginal dip in revenue QoQ, EBITDA levels maintained while investing for growth Quarter Q Variance (%) Diagnostic revenue decrease in INR crore Q1 FY22 Q4 FY22 Q1 FY23 Seq. YOY sequential quarter is about 3%, Revenue from operations 159.26 123.33 119.24 -3% -25% primar
Slide 13: Income Statement – Radiology
Income Statement – Radiology: Continued strong performance in revenue leading to improved margins Quarter Q Variance (%) Revenue from imaging services INR crore Q1 FY22 Q4 FY22 Q1 FY23 Seq. YOY accounted for 7% of reported Revenue from operations 5.39 7.22 8.55 18% 59% consolidated revenue of Cost o
Slide 14: Income Statement – Consolidated
Income Statement – Consolidated: Slight decline in revenues QoQ due to COVID mix change, EBITDA margins stable Quarter Q Variance (%) Overall revenue mix continues INR crore Q1 FY22 Q4 FY22 Q1 FY23 Seq. YOY to move away from COVID Revenue from operations 164.65 130.56 127.79 -2% -22% between the qua
Slide 15: Agenda
Agenda 1 What’s keeping us busy 2 Performance Summary 3 Looking ahead – priorities for the year 13
Slide 16: We continue to execute against our strategy shared in May
We continue to execute against our strategy shared in May – will remain focused on the execution against this agenda + 1 Serve Pharmeasy Online customer base of 2.1 M 5 Continue to improve our value proposition to quarterly transacting users our franchisee network, expand aggressively 2 Partner with
Slide 17: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,
Thyrocare Technologies — Q1 FY2022-23 Earnings Presentation on 6ix